The tariff classification of Acyclovir Tablets and Potassium Citrate Extended-Release Tablets, in dosage form, from India
Issued December 16, 2013 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 3004.90.9110, 3004.90.9170
Headings: 3004
Product description
The first product, Acyclovir Tablets, is a medicinal preparation in 400 mg and 800 mg, containing Acyclovir, an antiviral, as the active ingredient. It is indicated for the treatment of herpes zoster. The second product, Potassium Citrate Extended-Release Tablets, is a medicinal preparation, containing Potassium Citrate, as the active ingredient. It is indicated for the management of renal tubular acidosis.
CBP rationale
The applicable subheading for the Acyclovir Tablets in dosage form will be 3004.90.9110, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Anti-infective medicaments: Other. The applicable subheading for the Potassium Citrate Extended release Tablets in dosage form will be 3004.90.9170, Harmonized Tariff Schedule of the United States (HTSUS), which provides for "Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or in forms or packings for retail sale: Other: Other: Other: Preparations primarily affecting the electrolytic, caloric or water balance: Other.
Full text
N248031 December 16, 2013 CLA-2-30:OT:RR:NC:2:238 CATEGORY: Classification TARIFF NO.: 3004.90.9110; 3004.90.9170 Mr. Pradeep Shah Zydus Pharmaceuticals USA Inc. 73 Route 31 North Pennington, NJ 08534 RE: The tariff classification of Acyclovir Tablets and Potassium Citrate Extended-Release Tablets, in dosage form, from India Dear Mr. Shah: In your letter dated November 6, 2013, you requested a tariff classification ruling. The first product, Acyclovir Tablets, is a medicinal preparation in 400 mg and 800 mg, containing Acyclovir, an antiviral, as the active ingredient. It is indicated for the treatment of herpes zoster. The second product, Potassium Citrate Extended-Release Tablets, is a medicinal preparation, containing Potassium Citrate, as the active ingredient. It is indicated for the management of renal tubular acidosis. The applicable subheading for the Acyclovir Tablets in dosage form will be 3004.90.9110, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Anti-infective medicaments: Other.” The rate of duty will be free. The applicable subheading for the Potassium Citrate Extended release Tablets in dosage form will be 3004.90.9170, Harmonized Tariff Schedule of the United States (HTSUS), which provides for "Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or in forms or packings for retail sale: Other: Other: Other: Preparations primarily affecting the electrolytic, caloric or water balance: Other." The rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at (646) 733-3033. Sincerely, Gwenn Klein Kirschner Acting Director National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Clobetasol Propionate Spray and Entecavir Tablets in dosage form, from India
The tariff classification of Temozolomide capsules and Metronidazole tablets in dosage form, from India
The tariff classification of Linezolid tablets and Trazodone Hydrochloride tablets in dosage form, from India
The tariff classification of Amantadine Hydrochloride capsules and Acamprosate Calcium delayed release capsules in dosage form, from Spain and India, respectively
The tariff classification of Voriconazole Tablets in dosage form, from India
The tariff classification of Voriconazole Tablets and Nateglinide Tablets in dosage form, from Malta and India, respectively
The tariff classification of Nitrofurantoin Capsules USP (Macrocrystals), in dosage form, from India. Correction to Ruling Number N269197
The tariff classification of Nitrofurantoin Capsules USP (Macrocrystals), in dosage form, from India
The tariff classification of Metronidazole (CAS 443-48-1), in dosage form, from India
The tariff classification of Calcium Acetate Gelcaps, in dosage form, from Germany
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →